Previous 10 | Next 10 |
AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Capital raise closed in July, led by new healthcare investors; provides access to up to $26.3 million in capital, with $10 million immediately available AcelRx awaits...
AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023 PR Newswire HAYWARD, Calif. , July 27, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the developme...
AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq Rules PR Newswire Transformative capital raise, led by new investors including Nantahala Capital Management The private placement provides access to up ...
2023-07-18 08:39:23 ET Specialty pharmaceutical company AcelRx Pharmaceuticals ( NASDAQ: ACRX ) said on Tuesday that it has launched an ~$10M private placement of shares. The company has entered into a definitive agreement for the purchase and sale of an aggregate of 5.3M shar...
AcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules PR Newswire Upon the achievement of certain milestones accelerating the warrants' expiration date, AcelRx may receive an additional $16.3 million of gross p...
2023-05-10 20:28:06 ET AcelRx Pharmaceuticals, Inc. (ACRX) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Raffi Asadorian – Chief Financial Officer Vincent Angotti – Chief Executive Officer Pam Palmer – Co-Found...
2023-05-10 16:12:29 ET AcelRx Pharmaceuticals press release ( NASDAQ: ACRX ): Q1 GAAP EPS of -$0.75 beats by $0.04 . The cash and cash equivalents balance was $13.4 million as of March 31, 2023. Combined R&D and SG&A expenses for the first quarter of 2023 t...
AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Request for Emergency Use Authorization of Niyad™ submitted to the FDA in April Divestment of DSUVIA® to Alora Pharmaceuticals closed April 3, 20...
2023-05-09 17:35:57 ET AcelRx Pharmaceuticals ( NASDAQ: ACRX ) is scheduled to announce Q1 earnings results on Wednesday, May 10th, after market close. The consensus EPS Estimate is -$0.80 and the consensus Revenue Estimate is $1.65M (+275.0% Y/Y). Over the last 3 mont...
AcelRx to Host First Quarter 2023 Financial Results Call and Webcast on May 10, 2023 PR Newswire HAYWARD, Calif. , April 27, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development ...
News, Short Squeeze, Breakout and More Instantly...
AcelRx Pharmaceuticals Inc. Company Name:
ACRX Stock Symbol:
NASDAQ Market:
AcelRx Pharmaceuticals Inc. Website:
AcelRx Announces Rebranding With Name Change to Talphera, Inc. PR Newswire Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on ...
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States PR Newswire Use of CRRT increased during COVID and remained at these higher utilization levels Study results demonst...
Shares of Green Giant Inc. (NASDAQ: GGE) fell sharply in pre-market trading after announcing a proposed public offering. Green Giant shares dippe...